Rezolute RZLT 深 沪
等待开盘 04-03 09:30:00 美东时间
3.12
-0.010
-0.32%
华盛通- 最 高3.20
- 今 开3.03
- 成交量 68.56万股
- 最 低 2.99
- 昨 收 3.13
- 总市值 2.99亿
- 52周最高 11.4565
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 1.07
- 委 比 71.84%
- 总股本 9569.77万
- 历史最高 21.11
- 量 比 0.26
- 振 幅 6.71%
- 历史最低 0.72
- 每 手 1
- 风险率 2.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs
Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs Rezolute highlighted ersodetug (RZ358) as a late-stage antibody program targeting hypoglycemia across congenital hyperinsulinism and tumor-driven hyperinsulinism. Phase 3 sunRIZE study in congenital hyperinsulini
04-01 10:13
美股牛股 | SpaceX冲刺上市点燃情绪！太空概念Sidus大涨18%，Firefly涨超16%；ARM官宣下场造芯片
SpaceX冲刺上市点燃情绪！太空概念Sidus大涨18%，Firefly涨超16%；芯片设计巨头ARM单日飙涨16%，官宣亲自下场造芯片>>
03-26 18:52
美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
Wedbush Upgrades Rezolute to Outperform, Raises Price Target to $5
Wedbush analyst Yun Zhong upgrades Rezolute (NASDAQ:RZLT) from Neutral to Outperform and raises the price target from $2 to $5.
03-25 19:56
FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question
Rezolute shares rise after FDA feedback on sunRIZE trial; mixed efficacy, data review ahead for rare genetic disorder drug.
03-25 02:00
Rezolute gains after positive FDA meeting over lead asset
Rezolute (RZLT) shares traded higher on Tuesday after the company said that it was encouraged by the outcome of a meeting held with the U.S. FDA regarding a late-stage trial for its lead asset, ersode...
03-24 22:54
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Rezolute announced outcomes from an FDA Type B meeting regarding the sunRIZE Phase 3 study of ersodetug for congenital HI. While the study did not meet its primary endpoint due to a pronounced study effect, FDA acknowledged challenges with behavioral factors and limitations of SMBG metrics. The agency encouraged Rezolute to submit comprehensive data from sunRIZE and the open-label extension for independent evaluation. Rezolute expects an update o...
03-24 11:00
XOMA 2025 income, revenue jump on portfolio expansion, milestone payments
XOMA 2025 income, revenue jump on portfolio expansion, milestone payments Overview US biotech royalty aggregator's 2025 income and revenues rose 83% yr/yr to $52.1 mln Net income for 2025 turned positive at $31.7 mln, up from a $13.8 mln loss in 2024 Company repurchased $16 mln of shares and complet
03-18 18:10
XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million
XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million XOMA Royalty published a press release reporting Q4 and full-year 2025 financial results. FY 2025 income and revenues rose 83% to USD 52.15 million, driven primarily by higher income related to VABYSMO and OJEMDA and milestone payments from
03-18 18:01
Rezolute to Participate in the Citizens Life Sciences Conference
Rezolute, Inc., a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), announced that its management will participate in one-on-one investor meetings at the Citizens Life Sciences Conference in Miami, FL, on March 10-11, 2026. Investors can schedule meetings with Rezolute's management through their Citizens representative. Rezolute's antibody therapy, ersodetug, is designed to treat all forms of HI and ...
03-04 12:00
